Blinatumomab and low-dose DLI after transplant for B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 70 years old.
- You must have a diagnosis of high-risk B-ALL and be in remission (MRD-negative) after a stem cell transplant.
- Your liver and kidney function must be within certain limits.
- You must not have active graft-versus-host disease (GVHD) or uncontrolled infections.
- You must not be pregnant or breastfeeding.
- You must have no severe allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments—blinatumomab and a special type of immune cell called iNKT—to fight B-cell acute lymphoblastic leukemia (ALL) that has returned or is not responding well after prior treatment. The goal is to see if this combination is safe and effective for patients who have had a relapse or new minimal residual disease (MRD) after previous treatment.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
Hear when a new ALL (Acute B-Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.